The present invention relates to a composition for injection containing docetaxel, characterized by comprising: docetaxel or pharmaceutically acceptable salts thereof, hydroxypropyl-beta-cyclodextrin (HP-β-CD), polyethylene glycol, ethanol, and optionally an acidifier. The transparent liquid-phase composition for injection according to the present invention not only has excellent storage stability, but also has excellent fluid dilution stability, as can be seen in the absence of precipitation occurring during the period of administration when the composition is diluted in a fluid.La présente invention concerne une composition pour injection contenant du docétaxel, caractérisée en ce quelle comprend : du docétaxel ou un sel associé pharmaceutiquement acceptable, de lhydroxypropyl-bêta-cyclodextrine (HP-β-CD), du glycol polyéthylénique, de léthanol, et éventuellement un acidifiant. La composition en phase liquide transparente pour injection selon la présente invention présente non seulement une excellente stabilité au stockage, mais également une excellente stabilité de dilution de fluide, comme cela peut être constaté de par labsence de précipitation se produisant pendant la période dadministration lorsque la composition est diluée dans un fluide.본 발명은 도세탁셀을 함유하는 주사용 조성물에 관한 것으로서, 도세탁셀 또는 이의 약학적으로 허용 가능한 염, 하이드록시프로필-베타-사이클로덱스트린(HP-β-CD), 폴리에틸렌글라이콜, 에탄올 및 선택적으로 산성화제를 포함하는 것을 특징으로 한다. 본 발명에 따른 투명 액상 주사용 조성물은 보관 안정성이 우수할 뿐만 아니라, 수액으로 희석 시 투여시간 동안 침전이 일어나지 않는 등 수액 희석 안정성이 매우 우수하다.
